EZH2 and myeloid sarcoma: Although caution should be taken when considering these data owing to the small sample size and high variability, these findings altogether warrant additional studies to deepen into the pathogenic capacity of T cells expressing EZH2 and explore whether EZH2 may become a therapeutic target in MS patients to reduce disease activity.